Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 10Completed 5Active not recruiting 4Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 10Polycystic Ovary Syndrome 2Ovarian Neoplasms 2Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Leiomyoma 1Infertility, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Carcinoma In Situ 1Abortion, Spontaneous 1

Interventions

pembrolizumab 3NVP-BKM120 2Bevacizumab 2trastuzumab duocarmazine 1talazoparib 1sitravatinib 1ponatinib 1niraparib 1mirvetuximab soravtansine 1lenvatinib 1dostarlimab 1dactolisib 1bemarituzumab 1Trastuzumab 1Taxes 1TAS-116 1Sevoflurane 1Radiotherapy 1Propofol 1Proflavine 1Polymerase Chain Reaction 1Paclitaxel 1PM 01183 1Methods 1Metformin 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Letrozole 1Interviews as Topic 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Endometrial Neoplasms × Letrozole × Clear all
NCT05712941 2023-11-03

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

EQRx International, Inc.

Phase 3 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡